Apogee Therapeutics (APGE) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Apogee Therapeutics (APGE) EV/EBITDA fluctuations on GURU.Markets demonstrate volatility, where the value 0.00 represents the current metric. This trend captures the impact of clinical data cycles and the availability of venture capital investments. The foundation is a targeted therapy ecosystem featuring unique treatment protocols. However, the lack of sales and laboratory expenses associated with scaling research are temporarily keeping the operating leverage negative.

Apogee Pharma - APGE Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 09/19/2026)

Metric breakdowns and analytics for apogeetherapeutics.com (APGE)

- market price and analyst price targets:

Price Chart Apogee Pharma|APGE - Analyst Median Target

- market capitalization details:

Market Value Apogee Corp|APGE - Enterprise Value

- book value of equity indicators:

Book Value per Share Apogee Therapeutics|APGE - Book Valuation of Business|Market Value to Book Value Ratio apogeetherapeutics.com|APGE - Total Business Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

APGE - Company Net Income|Projected Future Earnings Apogee Therapeutics|APGE - Market Cap to Earnings|Projected Price to Earnings Apogee Therapeutics|APGE - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Apogee Corp|APGE - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Apogee Therapeutics|APGE - Earnings per share for the trailing year|Quarterly EPS earnings growth apogeetherapeutics.com|APGE - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Apogee Therapeutics

- sales volume and revenue indicators:

APGE - Company Sales Revenue|Projected Sales Volume Apogee Pharma|APGE - P/S Multiple|Price-to-Projected Revenue Ratio Apogee Corp

Fundamental valuation:APGE (Apogee Pharma)

Product sample of Apogee Therapeutics, Inc.

To minimize credit risks, it is essential for investors to monitor the ratio of total enterprise value to earnings before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA multiple trend, one can assess the debt load and margin sensitivity to the cost of capital, which for a non-cyclical biotech like Apogee Therapeutics (APGE) allows for the mitigation of financial shocks by shifting the focus toward R&D risks and patent protection.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Krystal Corp KRYS|Total Company Value to Operating Income Before Depreciation Ratio Arcutis Corp (ARQT)|VCEL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ORKA - EV/EBITDA Multiple|SMTI: EV/EBITDA Multiple|DBVT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Solesence Beauty|Enterprise Value to Operating Income Before Depreciation DERM (Journey Medical Corp.)|EV/EBITDA Multiple FBRX|EV/EBITDA Multiple empro.my (EMPG)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sol-Gel Technologies Ltd. SLGL|AXIL (AXIL Brands Inc) - Company Value to Operating Income Before Depreciation Ratio|MDCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Verrica Pharmaceuticals|HOTH: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Biofrontera BFRI|VYNE (VYNE Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Sonoma Pharma SNOA|EV/EBITDA Multiple QNRX|AZTR - Company Value to EBITDA|Dermata Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ELAB|RVNC: Enterprise Value to EBITDA Ratio